KURA logo

Kura Oncology (KURA) Company Overview

Profile

Full Name:

Kura Oncology, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

September 16, 2015

Indexes:

Not included

Description:

Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for cancer. They aim to improve treatment options for patients with various types of cancer by creating innovative drugs that specifically attack cancer cells while minimizing harm to healthy cells.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 8, 25 Scotiabank
Sector Perform
Dec 9, 24 Cantor Fitzgerald
Overweight
Nov 26, 24 Cantor Fitzgerald
Overweight
Nov 22, 24 B of A Securities
Buy
Nov 21, 24 TD Cowen
Buy
Nov 21, 24 Jefferies
Buy
Nov 21, 24 HC Wainwright & Co.
Buy
Nov 21, 24 Cantor Fitzgerald
Overweight
Nov 19, 24 JMP Securities
Market Outperform
Nov 18, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Kura Oncology Announces Senior Executive Promotions
Kura Oncology Announces Senior Executive Promotions
Kura Oncology Announces Senior Executive Promotions
KURA
globenewswire.comJanuary 6, 2025

– Mollie Leoni, M.D. promoted to Chief Medical Officer – – Francis Burrows, Ph.D.

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
KURA
seekingalpha.comDecember 18, 2024

Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura's lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan.

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
KURA
seekingalpha.comNovember 9, 2024

Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Peter Lawson - Barclays Justin Zelin - BTIG Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call.

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
KURA
globenewswire.comOctober 24, 2024

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
KURA
globenewswire.comSeptember 30, 2024

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled “Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial,” is now available on The Lancet Oncology website and in the Scientific Manuscripts section on Kura's website.

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
KURA
globenewswire.comSeptember 17, 2024

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership.

Kura Oncology to Report Second Quarter 2024 Financial Results
Kura Oncology to Report Second Quarter 2024 Financial Results
Kura Oncology to Report Second Quarter 2024 Financial Results
KURA
globenewswire.comAugust 1, 2024

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
KURA
globenewswire.comJune 24, 2024

– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
KURA
businesswire.comJune 11, 2024

SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disrupt the cycle of poverty and inequity throughout its communities, and Kura Oncology are continuing their partnership to support the San Diego community. Kura Oncology is contributing $100,000 through Life Science Cares' Basic Needs portfolio to support local nonprofit, Mama's Kitchen, with meeting.

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
KURA
Seeking AlphaMay 4, 2024

Kura Oncology, Inc. (NASDAQ:KURA) held its Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET. Present on the call were Pete De Spain, Troy Wilson, and Thomas Doyle from the company. Various analysts and investors also participated in the call. The operator welcomed all participants to the conference call, which was in listen-only mode.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Kura Oncology?
  • Does Kura Oncology pay dividends?
  • What sector is Kura Oncology in?
  • What industry is Kura Oncology in?
  • What country is Kura Oncology based in?
  • When did Kura Oncology go public?
  • Is Kura Oncology in the S&P 500?
  • Is Kura Oncology in the NASDAQ 100?
  • Is Kura Oncology in the Dow Jones?
  • When was Kura Oncology's last earnings report?
  • When does Kura Oncology report earnings?
  • Should I buy Kura Oncology stock now?

What is the ticker symbol for Kura Oncology?

The ticker symbol for Kura Oncology is NASDAQ:KURA

Does Kura Oncology pay dividends?

No, Kura Oncology does not pay dividends

What sector is Kura Oncology in?

Kura Oncology is in the Healthcare sector

What industry is Kura Oncology in?

Kura Oncology is in the Biotechnology industry

What country is Kura Oncology based in?

Kura Oncology is headquartered in United States

When did Kura Oncology go public?

Kura Oncology's initial public offering (IPO) was on September 16, 2015

Is Kura Oncology in the S&P 500?

No, Kura Oncology is not included in the S&P 500 index

Is Kura Oncology in the NASDAQ 100?

No, Kura Oncology is not included in the NASDAQ 100 index

Is Kura Oncology in the Dow Jones?

No, Kura Oncology is not included in the Dow Jones index

When was Kura Oncology's last earnings report?

Kura Oncology's most recent earnings report was on Nov 7, 2024

When does Kura Oncology report earnings?

The next expected earnings date for Kura Oncology is Feb 27, 2025

Should I buy Kura Oncology stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions